This study is currently not recruiting participants.

A Phase III Randomized Double-Blind Placebo-Controlled Study to Evaluate the Effects of Odanacatib (MK-0822) on Bone Mineral Density (BMD) and Overall Safety in the Treatment of Osteoporosis in Postmenopausal Women Previously Treated with an Oral Bispho

Study on Investigational Treatment for Osteoporosis (a condition where bones become weak) in Postmenopausal Women

Not Recruiting
60 years - 100 years
Female
Phase N/A
1 Location

Brief description of study.

The purpose of this study is to evaluate the effect of a new investigational drug for the treatment of osteoporosis in postmenopausal women.

Detailed description of study

The purpose of this study is to evaluate the effect of a new investigational drug for the treatment of osteoporosis in postmenopausal women.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: Osteoporosis
  • Age: 60 years - 100 years
  • Gender: Female

The purpose of this study is to evaluate the effect of an investigational drug for the treatment of osteoporosis in postmenopausal women. Osteoporosis is a condition where bones become weak and are more likely to break. This study investigates how the investigational treatment affects bone density and strength in women who have gone through menopause.

Participants will receive either the investigational medication or a placebo. A placebo is an inactive substance that looks like the investigational medication but does not contain any medicine. The study will involve regular assessments of bone density and health to determine the medication's effectiveness.

  • Who can participate: Participants must be postmenopausal women aged 50 to 75 years with a diagnosis of osteoporosis.
  • Study details: Participants will receive either the investigational medication or a placebo. A placebo is an inactive substance that looks like the investigational medication but does not contain any medicine.
Updated on 19 Feb 2024. Study ID: 1305011340

Interested in the study?

Select a study center that’s convenient for you, and get in touch with the study team.

Connect with the study team